our
pipelineTransMolecular is developing novel proprietary treatments to diagnose and treat cancer and other neovascular diseases, including those affecting the eye. Our lead compound, TM601, is currently in clinical studies to validate its imaging, tumor targeting and binding, drug delivery and anti-angiogenic applications. To date we have treated more than 150 patients in several cancer indications and plan to initiate studies in the ophthalmic disease, neovascular age-related macular degeneration. Research continues to elucidate the broad platform potential of TM601 in conjugated drug delivery of a range of imaging and therapeutic molecules.
